CDC Awards Quest Diagnostic [NYSE: DGX] Agreement To Provide The Genomic Sequence Of SARS-CoV-2 Virus.

Quest diagnostics [NYSE: DGX] a company that provides diagnostic information services revealed that the company inked a contract with the Center for disease control and prevention (CDC). In the agreement, the enterprises agreed to provide genomic sequencing. The genomic sequencing will be provided so that they can detect new spreading patterns and transformations in SARS-CoV-2. SARS-CoV-2 is a virus that causes Covid.

The main aim of this partnership is to help CDC in conducting a genomic survey of the SARS-CoV-2 virus. CDC will conduct a longitudinal analysis by utilizing an arbitrary set of a sample. Quest lab in the US will provide the sample. CDC will execute genomic sequencing from California’s advanced diagnostic laboratory.

To provide molecular diagnostic testing for SARS-CoV-2, the company will sequence the genome of arbitrary de-identify samples that test positive. Moreover, Quest diagnostics will give the entire completed genomic sequence to CDC. CDC will combine this data with others it received from national, state, and academics labs to achieve the aims of the Survey.

“ The collaboration between the public and private sector is important to mobilize a compelling reaction to COVID-19.  Our company has skills in genetics and viral diseases also the company has a broad range of Covid 19 testing data and access to patient samples. This partnership will aid CDC in accelerating and expanding the effort to detect new virus transformations. Additionally, help CDC improve public health response to the epidemic”. Said Jay G. Wohlgemuth M.D, SVP, and CMO of Quest.

The CDC’s survey analysis plans to give significant baseline data to public and state-level observation and inspection. Moreover, it will help characterize changes in the spreading patterns, distinguish new variations of the virus. It will also and improve the general health reaction to the virus.